Total (n=21) | Non-survivor (n=5) | Survivor (n=16) | P value | |
Treatment | ||||
ICU admission | 5 (23.8%) | 4 (80.0%) | 1 (6.3%) | 0.004* |
Antiviral treatment | 17 (81.0%) | 4 (80.0%) | 13 (81.3%) | 1.000 |
Antibiotic treatment | 15 (71.4%) | 5 (100.0%) | 10 (62.5%) | 0.262 |
Glucocorticoids | 8 (38.1%) | 5 (100.0%) | 3 (18.8%) | 0.003* |
Intravenous immunoglobulin | 5 (23.8%) | 3 (60.0%) | 2 (12.5%) | 0.063 |
Non-invasive ventilation | 4 (19.0%) | 3 (60.0%) | 1 (6.3%) | 0.028* |
Invasive mechanical ventilation | 3 (14.3%) | 3 (60.0%) | 0 (0.0%) | 0.008* |
CRRT | 2 (9.5%) | 2 (40.0%) | 0 (0.0%) | 0.048* |
ECMO | 2 (9.5%) | 2 (40.0%) | 0 (0.0%) | 0.048* |
Complications during hospitalisation | ||||
Secondary infection | 6 (28.6%) | 3 (60.0%) | 3 (18.8%) | 0.115 |
Ascites | 5 (23.8%) | 2 (40.0%) | 3 (18.8%) | 0.553 |
Upper GI bleeding | 4 (19.0%) | 3 (60.0%) | 1 (6.3%) | 0.028* |
Acute-on-chronic liver failure | 1 (4.8%) | 1 (20.0%) | 0 (0.0%) | 0.238 |
Acute kidney injury | 1 (4.8%) | 1 (20.0%) | 0 (0.0%) | 0.238 |
Septic shock | 3 (14.3%) | 2 (40.0%) | 1 (6.3%) | 0.128 |
ARDS | 6 (28.6%) | 5 (100.0%) | 1 (6.3%) | <0.001* |
Length of stay, days | 16 (11–32) | 16 (7–39) | 16 (11–31) | 0.842 |
One patient died in the emergency department without intensive care. Data are expressed as median (IQR) or n (%). P values were calculated by Mann-Whitney U test or Fisher’s exact test, as appropriate.
*A two-sided p-value of less than 0.05 was considered statistically significant.
ARDS, acute respiratory distress syndrome; CRRT, continuous renal replacement therapy; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit.